Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

14.10

Mkt cap

1.2B

Volume

949K

High

14.47

P/E Ratio

-8.91

52-wk high

16.99

Low

14.05

Div yield

N/A

52-wk low

8.26

Liquidia Corporation will announce its full year 2024 financial results on March 19, 2025. The company focuses on developing therapies for rare cardiopulmonary diseases.

Portfolio Pulse from

March 12, 2025 | 12:15 pm

Liquidia Technologies (LQDA) saw a significant price increase of 5.7% in the last trading session, driven by higher-than-average trading volume. However, the current trend in earnings estimate revisions may not support continued upward movement in the near term.

Portfolio Pulse from

January 22, 2025 | 3:30 pm

Analysts predict a potential 132.54% upside for Liquidia Technologies (LQDA) stock, based on the mean of their price targets. Despite the historical ineffectiveness of this metric, the consensus on raising earnings estimates suggests a positive outlook.

Portfolio Pulse from

December 12, 2024 | 4:00 pm

Wall Street analysts have set a consensus price target for Liquidia Technologies (LQDA) that suggests a potential upside of 126.1%. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions could indicate a near-term upside for the stock.

Portfolio Pulse from

November 26, 2024 | 4:00 pm

Liquidia Corporation's Yutrepia, a competitor to United Therapeutics' Tyvaso, is expected to enter the market in 2025. Despite financial challenges and competition, Liquidia's low valuation and upcoming product launches make it an attractive investment. Legal battles with United Therapeutics are nearing resolution, potentially allowing Yutrepia's commercial launch by mid-2025.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

Liquidia Corporation held its Q3 2024 earnings call, discussing financial results and corporate updates. Key executives participated, and analysts from various financial institutions attended.

Portfolio Pulse from

November 13, 2024 | 8:00 pm

Liquidia Technologies, Inc. (LQDA) reported a Q3 loss of $0.37 per share, matching the Zacks Consensus Estimate, but showed an improvement in revenue compared to expectations.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

Liquidia Corporation reported its Q3 2024 financial results, highlighting a tentative FDA approval for YUTREPIA™ and a Supreme Court victory regarding patent disputes. The company also raised $100 million in capital.

Portfolio Pulse from

November 13, 2024 | 11:45 am

Pomerantz Law Firm is investigating claims on behalf of investors of Liquidia Corporation (NASDAQ:LQDA). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Scotiabank has initiated coverage on Liquidia with a Sector Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 2:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.